Maribavir for cytomegalovirus infection after a transplant in South Korea
Looks at how maribavir works and its safety for cytomegalovirus after transplant.
Key facts
- Who runs it
- Takeda
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
- Status
- Recruiting
- People taking part
- 168 people, planned
- Started
- 14 Nov 2024
- Expected to end
- 1 Oct 2028
- Type of study
- Observational
- Treatments tested
- LIVTENCITY
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in South Korea with CMV infection after a transplant. Their CMV did not respond to, or resisted, earlier treatment. They are starting LIVTENCITY (maribavir) for the first time.
- Age
- 19 years or older.
- Sex
- All sexes can join.
- Disease stage
- CMV infection and/or disease after a transplant. It is refractory and/or resistant: earlier treatment did not work or the virus resists it.
- Earlier treatment
- People must have had one or more earlier treatments, such as ganciclovir, valganciclovir, cidofovir or foscarnet. People who already had maribavir in a study or as a marketed drug cannot join.
Main reasons for not taking part
- People who must not take LIVTENCITY Tablet (maribavir) according to the product label.
- People who had maribavir before, in a study or as a marketed drug.
- People taking part in other clinical trials of post-transplant CMV treatment.
- People getting other experimental treatments.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants with post-transplant CMV infection and/or disease who are refractory and/or resistant to one or more prior therapy including ganciclovir, valganciclovir, cidofovir or foscarnet
- Participants with age greater than or equal to (>=) 19 years
- Initiate first treatment course with maribavir
- Voluntarily consent to participate in the study
Who cannot take part
- Participants previously treated with maribavir in any study or as marketed drug
- Participants actively participating in other clinical trials of post-transplant CMV infection treatment or with other experimental treatments
- Participants for whom LIVTENCITY Tablet (maribavir) is contraindicated as per product label
Where in South Korea
- The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaContact: Cho Seong-yeon (principal investigator)Taking people
About the trial
What the trial wants to find out
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. LIVTENCITY (Maribavir) is a medicine approved for treating CMV infection in adults after transplant in South Korea.
Read full original descriptionShow less
The main aim of this study is to learn how safe and effective LIVTENCITY (Maribavir) is in treating adults with CMV infection after transplant in a routine clinical practice setting.
During the study, a participant's data will be collected for about 5 months (20 weeks). The study does not have fixed visits to the hospital, but it is recommended to visit the study doctor approximately 6 times during study.
The group in the trial
- All Participants
Participants with post-transplant CMV infection and/or disease who are refractory and/or resistant to one or more prior therapy (including ganciclovir, valganciclovir, foscarnet or cidofovir) will be treated with LIVTENCITY tablet as per treating physician's discretion in a routine clinical practice setting, according to the approved labelling and will be observed prospectively for up to a 20-week period.
Treatment: LIVTENCITY
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post-Marketing Surveillance (Usage Results Study) of LIVTENCITY Tablet (Maribavir) for the Approved Indications in South Korea
- Plain-language title
- Maribavir for cytomegalovirus infection after a transplant in South KoreaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 6 November 2026